3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Leukemia, Prolymphocytic, B-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Myeloid, Acute
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Myeloid
1
Leukemia, Large Granular Lymphocytic
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Cytarabine
14
fludarabine
13
venetoclax
11
Imatinib Mesylate
9
Cyclophosphamide
8
Azacitidine
8
fludarabine phosphate
7
Busulfan
7
Whole-Body Irradiation
6
Tacrolimus
6
Mycophenolic Acid
6
thymoglobulin
4
ponatinib
4
nilotinib
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
asciminib
3
aldesleukin
3
Melphalan
3
Interleukin-2
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Decitabine
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
zosuquidar trihydrochloride
2
gilteritinib
2
enasidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid
×
Sensitivity and Specificity
×
Other hematologic neoplasm
×
Clear all
NCT01864902
2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled